Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer

European Urology

Volumn 70, Issue 5, 2016, Pages 829-836

  Eiber, Matthias ^a   Weirich, Gregor ^a   Holzapfel, Konstantin ^a   Souvatzoglou, Michael ^a,b   Haller, Bernhard ^a   Rauscher, Isabel ^a   Beer, Ambros J ^a,b   Wester, Hans Jürgen ^c   Gschwend, Juergen ^a   Schwaiger, Markus ^a   Maurer, Tobias ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

68Ga PSMA HBED CC PET MRI; Histopathology; Localization; mpMRI; Primary prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN HBED CC GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GALLIUM;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CHRONIC PROSTATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR VOLUME; YOUDEN INDEX; AGED; BIOPSY; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DIMENSIONAL MEASUREMENT ACCURACY; GERMANY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC;

AGED; BIOPSY; COMPARATIVE EFFECTIVENESS RESEARCH; DIMENSIONAL MEASUREMENT ACCURACY; GALLIUM RADIOISOTOPES; GERMANY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; ROC CURVE;

EID: 84956494500     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.12.053     Document Type: Article

References (39)

1. [1] Schröder, F.H., Hugosson, J., Roobol, M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009), 1320–1328.
2. [2] Schwartz, L.H., Basch, E., MR/ultrasound fusion-guided biopsy in prostate cancer: what is the evidentiary standard?. JAMA 313 (2015), 367–368.
3. [3] Sciarra, A., Barentsz, J., Bjartell, A., et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 59 (2011), 962–977.
4. [4] Hoeks, C.M.A., Barentsz, J.O., Hambrock, T., et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 261 (2011), 46–66.
5. [5] Hricak, H., Choyke, P.L., Eberhardt, S.C., Leibel, S.A., Scardino, P.T., Imaging prostate cancer: a multidisciplinary perspective. Radiology 243 (2007), 28–53.
6. [6] Dianat, S.S., Carter, H.B., Macura, K.J., Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer. Urol Oncol, 32, 2014 39.e1–10.
7. [7] Barentsz, J.O., Richenberg, J., Clements, R., et al. ESUR prostate MR guidelines 2012. Eur Radiol 22 (2012), 746–757.
8. [8] Dickinson, L., Ahmed, H.U., Allen, C., et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59 (2011), 477–494.
9. [9] Wibmer, A.G., Burger, I.A., Sala, E., Hricak, H., Weber, W.A., Vargas, H.A., Molecular imaging of prostate cancer. Radiographics 36 (2016), 142–159.
10. [10] Oyama, N., Akino, H., Suzuki, Y., et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29 (1999), 623–629.
11. [11] Souvatzoglou, M., Weirich, G., Schwarzenboeck, S., et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res Off J Am Assoc Cancer Res 17 (2011), 3751–3759.
12. [12] Farsad, M., Schiavina, R., Castellucci, P., et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46 (2005), 1642–1649.
13. [13] Silver, D.A., Pellicer, I., Fair, W.R., Heston, W.D., Cordon-Cardo, C., Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3 (1997), 81–85.
14. [14] Mease, R.C., Foss, C.A., Pomper, M.G., PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 13 (2013), 951–962.
15. [15] Eder, M., Schäfer, M., Bauder-Wüst, U., et al. 68Ga-Complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23 (2012), 688–697.
16. [16] Afshar-Oromieh, A., Zechmann, C.M., Malcher, A., et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41 (2014), 11–20.
17. [17] Eiber, M., Maurer, T., Souvatzoglou, M., et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56 (2015), 668–674.
18. [18] Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of 68Gallium-PSMA-PET compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high-risk prostate cancer. J Urol. In press. http://dx.doi.org/10.1016/j.juro.2015.12.025.
19. [19] D'Amico, A.V., Whittington, R., Malkowicz, S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998), 969–974.
20. 68Ga]CPCR4.2. Nucl Med Biol 41 (2014), 84–89.
21. [21] Drzezga, A., Souvatzoglou, M., Eiber, M., et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53 (2012), 845–855.
22. [22] Souvatzoglou, M., Eiber, M., Martinez-Moeller, A., et al. PET/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging 40 Suppl 1 (2013), S79–S88.
23. [23] Tango, T., Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 17 (1998), 891–908.
24. [24] Obuchowski, N.A., Nonparametric analysis of clustered ROC curve data. Biometrics 53 (1997), 567–578.
25. [25] Liang, K.-Y., Zeger, S.L., Longitudinal data analysis using generalized linear models. Biometrika 73 (1986), 13–22.
26. [26] Smith, P.J., Hadgu, A., Sensitivity and specificity for correlated observations. Stat Med 11 (1992), 1503–1509.
27. [27] Genders, T.S.S., Spronk, S., Stijnen, T., Steyerberg, E.W., Lesaffre, E., Hunink, M.G.M., Methods for calculating sensitivity and specificity of clustered data: a tutorial. Radiology 265 (2012), 910–916.
28. [28] Amsellem-Ouazana, D., Younes, P., Conquy, S., et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 47 (2005), 582–586.
29. [29] Hoeks, C.M.A., Hambrock, T., Yakar, D., et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology 266 (2013), 207–217.
30. [30] Hara, N., Okuizumi, M., Koike, H., Kawaguchi, M., Bilim, V., Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 62 (2005), 140–147.
31. [31] Hamoen, E.H.J., de Rooij, M., Witjes, J.A., Barentsz, J.O., Rovers, M.M., Use of the Prostate Imaging Reporting and Data System (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. Eur Urol 67 (2015), 1112–1121.
32. [32] Jambor, I., Borra, R., Kemppainen, J., et al. Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT. Eur J Radiol 81 (2012), 2966–2972.
33. [33] Hartenbach, M., Hartenbach, S., Bechtloff, W., et al. Combined PET/MRI Improves diagnostic accuracy in patients with prostate cancer: a prospective diagnostic trial. Clin Cancer Res 20 (2014), 3244–3253.
34. [34] Tamada, T., Sone, T., Jo, Y., et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 28 (2008), 720–726.
35. [35] Budäus, L., Leyh-Bannurah, S.-R., Salomon, G., et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69 (2016), 393–396.
36. [36] Terris, M.K., Prostate biopsy strategies: past, present, and future. Urol Clin North Am 29 (2002), 205–212 xi.
37. [37] Rud, E., Klotz, D., Rennesund, K., et al. Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone. BJU Int 114 (2014), E32–E42.
38. [38] Roethke, M.C., Lichy, M.P., Jurgschat, L., et al. Tumor size dependent detection rate of endorectal MRI of prostate cancer–a histopathologic correlation with whole-mount sections in 70 patients with prostate cancer. Eur J Radiol 79 (2011), 189–195.
39. [39] Hijazi, S., Meller, B., Leitsmann, C., et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by (68) Ga-PSMA-positron emission tomography/computerized tomography. Prostate 75 (2015), 1934–1940.